There are currently 990 clinical trials in Tampa, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Moffitt Cancer Center, University of South Florida, H. Lee Moffitt Cancer Center and Research Institute and Tampa General Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Using Aspirin to Improve Immunological Features of Ovarian Tumors
NCT05080946
Recruiting
The purpose of the study is to evaluate the effectiveness of aspirin with neoadjuvant chemotherapy for decreasing markers of immune suppression in the tumor at interval debulking surgery, in women with diagnosed ovarian, fallopian tube, or peritoneal carcinoma
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Register for Updates
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
NCT05170334
Recruiting
This research study is investigating Binimetinib and Belinostat in participants with metastatic uveal melanoma. The research study will test the study drugs to see if the combination of binimetinib and belinostat can make tumors shrink or stop growing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Metastatic Uveal Melanoma
Register for Updates
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
NCT05378464
Recruiting
The purpose of this study is to test the safety of Adoptive T-Cell therapy following the Dendritic Cell (DC1) study vaccine given in combination with pepinemab added to standard of care therapy, trastuzumab to help people with HER2 positive breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: HER2-positive Breast Cancer
Register for Updates
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
NCT05524935
Recruiting
This is a prospective phase II multi-center trial of the combination of the PARP inhibitor olaparib with the immune checkpoint inhibitor pembrolizumab in advanced uveal melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Uveal Melanoma, Ocular Melanoma
Register for Updates
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)
NCT05605093
Recruiting
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi \&; Co. Ltd. The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of ensitrelvir when given in addit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Tampa General Hospital (032-001), Tampa, Florida
Conditions: COVID-19
Register for Updates
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
NCT05711940
Recruiting
Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: University South Florida, Tampa, Florida
Conditions: Treatment Resistant Depression
Register for Updates
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
NCT05757219
Recruiting
The purpose of the study is to assess the safety and efficacy of once daily itacitinib oral administration in participants with diffuse large B-cell lymphoma (DLBCL) who will receive CAR-T cell therapy with axicabtagene ciloleucel (axi-cel).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Diffuse Large B Cell Lymphoma
Register for Updates
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
NCT05809752
Recruiting
The purpose of this study is to learn about the effects of the study treatment, Dendritic Cell Vaccine (DCV), to find the highest dose of the study treatment that can be given safely to Breast Cancer patients with Leptomeningeal Disease
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Leptomeningeal Disease, Triple Negative Breast Cancer, HER2-positive Breast Cancer
Register for Updates
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
NCT06104592
Recruiting
This is a phase 2, single-arm, open-label study to evaluate the safety and efficacy of comprehensive bridging radiation therapy prior to CD19 CAR T-cell therapy for large B-cell lymphoma patients with bulky disease, defined as any lesion ≥5 cm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
Register for Updates
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
NCT06401421
Recruiting
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: St. Joseph's Women's Hospital, Tampa, Florida
Conditions: Breast Cancer
Register for Updates
Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy
NCT06660355
Recruiting
Allogeneic transplant is potentially curative for hematological malignancies but its use is limited by the development of GVHD. Ruxolitinib now has FDA approval for treatment of chronic GVHD that has failed 1-2 prior lines of therapy based on a prior large, randomized phase III study. Given this evidence of safety and efficacy in the early refractory setting (after prednisone failure), Ruxolitinib represents an ideal agent to test in the primary therapy setting. Here investigators propose a phas... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Chronic Graft-versus-host Disease (cGVHD)
Register for Updates
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
NCT06684847
Recruiting
The main purpose of the proposed study is to evaluate the efficacy of efgartigimod PH20 SC in patients with moderate-to-severe Primary Sjögren's Disease (pSjD). The study consists of a double-blinded placebo-controlled treatment period and an open-label treatment period. The maximum study duration for participants in both study parts is approximately 105 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Clinical Research of West Florida, Inc., Tampa, Florida
Conditions: Primary Sjogrens Disease
Register for Updates